Formoterol Fumarate
Phase 3Small molecule
AstraZenecaFormoterol Fumarate is a small molecule that works as a Beta-2 Adrenergic Receptor Agonist.[2] It is being investigated across 6 indications, with its most advanced program in Phase 3.[1]
Formoterol Fumarate is one of 134 small molecule programs targeting Emphysema. It is currently in Phase 3.
6
Indications
41
Total Trials
1
Active Trials
133
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1050 competitors in Asthma
#DrugCompanyPhaseTrials
1Formoterol Fumarate
AstraZenecaPhase 3
Nucala
GGlaxo Dba Glaxosmithkline
Preclinical
Cinqair
TevaPreclinical
Spiriva
Boehringer IngelheimPreclinical
Qvar
Chiesi Farmaceutici S.p.A.Preclinical
Atrovent
Boehringer IngelheimPreclinical
Vit D
PPost Graduate Institute of Medical Education and Research, Chandigarh
Preclinical
Ozone
TTanta University
Preclinical
Lexapro
SShirley Ryan AbilityLab
Preclinical
Biological Drug
UUniversitaire Ziekenhuizen KU Leuven
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Obstructive Pulmonary Disease11 trials
Show 8 more trials
Asthma8 trials
Show 5 more trials
Replication of the P04334 Asthma Trial in Healthcare Claims Data
Completed·—··NCT04892758·10,288 enrolled
Efficacy and Safety5 trials
COPD5 trials
9 more indications
MPA1 trial
Function1 trial
RCT1 trial
Moderate to Severe COPD1 trial
Efficacy1 trial
Complication1 trial
Perioperative Inhaled Therapy in Carcinological Thoracic Surgery in Patients at High Risk of Postoperative Pulmonary Complications
Recruiting·—·N/A·NCT06865040·266 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Formoterol Fumarate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Beta-2 Adrenergic Receptor Agonist[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company